• Star Icon
  • Star Icon
  • Star Icon

Erik is a Member of the firm whose primary areas of interest and experience include pharmaceutical, medical products liability and medical professional liability. He is also active in commercial litigation, employment discrimination and wrongful discharge claims and workplace exposure and injury litigation. Erik is the Firm’s Practice Leader for pharmaceutical litigation, and he has extensive experience in numerous drug and medical device litigations including those involving antidepressants, statins, COX2 inhibitors, hormone replacement therapy agents, antiplatelets, intraoperative anti-clotting agents, proton-pump inhibitors and implantable pelvic mesh devices. In this capacity, he has represented several Fortune 500 companies.

Erik has been recognized by his peers with an AV Martindale Hubbell rating and inclusion in The Best Lawyers in America® (Medical Malpractice Law), Chambers USA (Litigation-Healthcare Band 2), and West Virginia Super Lawyers (Personal Injury Defense – Products).

He is a member of the International Associate of Defense Counsel (IADC) and of the Defense Research Institute (DRI). Erik is a Past President of Defense Trial Counsel of West Virginia. He is admitted to practice in the state and federal courts of West Virginia, Kentucky and Ohio. He is a member of the American, West Virginia and Cabell County Bar Associations.

Erik has given numerous presentations and panel discussions on litigation practice and on substantive law topics relating to his areas of practice. He has served as an adjunct instructor for Marshall University’s School of Pharmacy (Pharmacy Law) and for the Marshall University College of Business (Legal Environment of Business undergraduate course), and has participated as a co-presenter for Pharmacy Law cumulative board review seminars for the University of Charleston (WV) School of Pharmacy and the Marshall University School of Pharmacy.

RIGHT FIRM. RIGHT NOW. | CALL (304) 522-9100


  • This field is for validation purposes and should be left unchanged.